Pacira BioSciences, Inc. (PCRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:16PM EDT. Market open.
| Previous close | 26.05 |
| Open | 25.86 |
| Bid | 25.93 x 100 |
| Ask | 26.00 x 100 |
| Day's range | 25.61 - 26.18 |
| 52-week range | 25.33 - 47.01 |
| Volume | |
| Avg. volume | 503,332 |
| Market cap | 1.207B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 29.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...
- Insider Monkey
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts. To skip our analysis of the recent market activity, you can go directly to see the Aggressive Stock Portfolio: 5 Stocks Picked by Analysts. By definition, aggressive stocks are ones that offer higher returns than conservative and relatively […]
- Zacks
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
© 2024 Yahoo. All rights reserved.